Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis.
Shahrokh F ShariatTatsushi KawadaKeiichiro MoriSung Ryul ShimHadi MostafaiReza Sari MotlaghFahad QuhalEkaterina LaukhtinaMarkus von DeimlingAlberto BianchiMuhammad MajdoubMaximilian PallaufBenjamin PradereTakahiro KimuraShahrokh F ShariatPaweł RajwaPublished in: BJU international (2023)
Among RCTs, novel systemic therapies seem to benefit the OS of patients with PCa irrespective of PS. Our findings suggest that worse PS should not discourage treatment intensification across all disease stages.